三周下降20%很棒，祝福
Belinda 发表于 2013-5-15 18:29 static/image/common/back.gif
滴水加油！为你家高兴！替单药效果不错啊！
我家是腺，已经替+凡德5天了，希望也能像你家一样有效啊！
谢谢，希望大家都找到更多的有效药物。
站直了别趴下 发表于 2013-5-15 19:24 static/image/common/back.gif
三周下降20%很棒，祝福
感谢，大家一起努力。
为楼主高兴，同时也考虑我父亲下步用替的可能性！关注中
体表面积和吉非替尼效果之间的关系：
http://abstracts2.asco.org/AbstView_132_112174.html
Impact of body surface area (BSA) on efficacy of gefitinib in patients with non-small cell lung cancer (NSCLC).
Results: Median BSA of the subjects was 1.42 m2 (range: 0.98-1.95). At the cutoff level in BSA of 1.50 m2, overall survival (OS) and PFS in the large BSA group were not different from those in the small BSA group in the univariate analysis, which was also shown in multivariate analysis (hazard ratio: 1.12, 95% confidence interval: 0.66-1.92 and 1.67, 0.86-3.44, respectively). Among subjects with EGFR-mutant tumors (n=125; 81%), BSA had no association with OS, but patients with larger BSA had significantly worse PFS in the multivariate analysis (1.59, 1.01-2.51). The association of BSA with PFS was highly sensitive to increase or decrease in the cutoff level of BSA: BSA ≥ 1.45 m2 vs. <1.45 m2, ; BSA ≥ 1.55 m2 vs. <1.55 m2, ; BSA ≥ 1.60 m2 vs. <1.60 m2, .Conclusions: In this cohort, PFS was significantly associated with BSA in EGFR-mutant NSCLC when BSA level was cut off by around the median score. Our findings might suggest the need for further investigation of dose finding PK/PD study stratified by BSA level in gefitinib therapy in EGFR-mutant NSCLC.
本帖最后由 滴水 于 2013-5-27 11:13 编辑
5.24恢复替吉奥，本打算改成100mg/d(减少20mg)，但父亲还是按照120mg/d吃的，这次准备吃2周停1周。
最近两侧肩窝有点疼，不知道什么原因。
请教过平安老师，两侧肩窝疼，可能是锁骨上淋巴引起的，可用B超确诊。如果是淋巴的问题，也是要通过药物控制才行，不单独处理淋巴。现在是右侧能摸到淋巴，左侧摸不到，锁骨上淋巴触诊未必能发现，还是要靠B超。
第一天开始疼是停2992上替吉奥的那天，期间有反复。准备观察几天，看这次上第二周期替吉奥后会不会好转。如果没好转，就去医院检查，有效就继续替吉奥，无效则上多西他赛+奈达铂。
你家吃替时还吃什么辅助的药？譬如营养神经的，保护肝脏等的？
滴水你好，请问你父亲的胸痛控制的怎么样
靠近椎体的骨转移是否考虑处理一下呢？我家人也是胸椎转移，疼痛，想参考一下，谢谢